Studies have shown that prolonged treatment with IL-6 receptor (IL-6R) antibodies can block IL-6 signaling and reduce muscle atrophy in tumor-bearing mice, suggesting that anti-IL-6 receptor antibodies could have therapeutic potential in addressing cancer-associated muscle wasting (177). The gene discussed is IL6; the disease is cancer.